SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang, Association between response to pegylated interferon/ribavirin therapy and ribavirin levels, Hepatology, 2015, 61, 1
  2. 2
    Edward J. Gane, Paul J. Pockros, Stefan Zeuzem, Patrick Marcellin, Anna Shikhman, Coen Bernaards, Julian Zhou, Ellen S. Yetzer, Rosa Ballester, Cindy Dwyer, Xiao Tong, Isabel Nájera, Anne Bertasso, Janet Hammond, Amy Kindrick, Peter N. Morcos, Patrick Smith, Saray Stancic, Nancy S. Shulman, Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study, Liver International, 2015, 35, 1
  3. 3
    Nicole M. Welch, Donald M. Jensen, Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C, Liver International, 2015, 35,
  4. 4
    Jordan J. Feld, Ira M. Jacobson, Donald M. Jensen, Graham R. Foster, Stanislas Pol, Edward Tam, Maciej Jablkowski, Hanna Berak, John M. Vierling, Eric M. Yoshida, Héctor R. Perez-Gomez, Astrid Scalori, Gregory J. Hooper, Jorge A. Tavel, Mercidita T. Navarro, Saba Shahdad, Rohit Kulkarni, Sophie Le Pogam, Isabel Nájera, Simon Eng, Chin Yin Lim, Nancy S. Shulman, Ellen S. Yetzer, Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin, Journal of Hepatology, 2015, 62, 2, 294

    CrossRef

  5. 5
    Manogna Nookathota, Sandeep Mukherjee, Antiviral therapy for chronic hepatitis C in 2014, Expert Review of Clinical Pharmacology, 2014, 7, 4, 499

    CrossRef

  6. 6
    Steven J. Coats, Ethel C. Garnier-Amblard, Franck Amblard, Maryam Ehteshami, Sheida Amiralaei, Hongwang Zhang, Longhu Zhou, Sebastien R.L. Boucle, Xiao Lu, Lavanya Bondada, Jadd R. Shelton, Hao Li, Peng Liu, Chengwei Li, Jong Hyun Cho, Satish N. Chavre, Shaoman Zhou, Judy Mathew, Raymond F. Schinazi, Chutes and ladders in hepatitis C nucleoside drug development, Antiviral Research, 2014, 102, 119

    CrossRef

  7. 7
    Erik De Clercq, Current race in the development of DAAs (direct-acting antivirals) against HCV, Biochemical Pharmacology, 2014, 89, 4, 441

    CrossRef

  8. 8
    Isabel Fofana, Nikolaus Jilg, Raymond T. Chung, Thomas F. Baumert, Entry inhibitors and future treatment of hepatitis C, Antiviral Research, 2014, 104, 136

    CrossRef

  9. 9
    M.G. Deneke, J.A. Dranoff, A. Duarte-Rojo, Erradicación exitosa del virus de la hepatitis C, genotipo 4, con terapia triple antiviral estándar más telaprevir, Revista de Gastroenterología de México, 2014, 79, 1, 64

    CrossRef

  10. 10
    X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, V. Baronas, J.-M. Yan, S.-S. So, K. Klumpp, I. Najera, In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir, Journal of Infectious Diseases, 2014, 209, 5, 668

    CrossRef

  11. 11
    H. Konishi, T. Motomura, Y. Matsumoto, N. Harimoto, T. Ikegami, T. Yoshizumi, Y. Soejima, K. Shirabe, T. Fukuhara, Y. Maehara, Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant, Journal of Viral Hepatitis, 2014, 21, 6
  12. 12
    Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia, Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus, Expert Opinion on Investigational Drugs, 2014, 23, 9, 1211

    CrossRef

  13. 13
    JS Au, PJ Pockros, Novel Therapeutic Approaches for Hepatitis C, Clinical Pharmacology & Therapeutics, 2014, 95, 1
  14. 14
    M.G. Deneke, J.A. Dranoff, A. Duarte-Rojo, Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy, Revista de Gastroenterología de México (English Edition), 2014, 79, 1, 64

    CrossRef

  15. 15
    Ya-Chi Chen, Coen Bernaards, Rohit Kulkarni, Sebastian Moreira, Yonghong Zhu, Anna Chan, Ethan Badman, Andrew Ackrill, James Thommes, Patrick F. Smith, Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies, British Journal of Clinical Pharmacology, 2014, 78, 3
  16. 16
    Eva Poveda, David L. Wyles, Álvaro Mena, José D. Pedreira, Ángeles Castro-Iglesias, Edward Cachay, Update on hepatitis C virus resistance to direct-acting antiviral agents, Antiviral Research, 2014, 108, 181

    CrossRef

  17. 17
    Jerome Deval, Martin Huber, Cancer-Causing Viruses and Their Inhibitors, 2014,

    CrossRef

  18. 18
    Heiner Wedemeyer, Donald Jensen, Robert Herring, Peter Ferenci, Mang-Ming Ma, Stefan Zeuzem, Maribel Rodriguez-Torres, Natalie Bzowej, Paul Pockros, John Vierling, David Ipe, Marie Lou Munson, Ya-Chi Chen, Isabel Najera, James Thommes, PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients, Hepatology, 2013, 58, 2
  19. 19
    Isabel Najera, Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase, Current Opinion in Virology, 2013, 3, 5, 508

    CrossRef

  20. 20
    Dawn M. Torres, Stephen A. Harrison, Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials, Hepatology, 2013, 58, 2